相关实验视频

Updated: Jun 8, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

描述Aptamer与瘤病毒VV-GMCSF-Lact的相互作用

Maya A Dymova¹, Daria O Malysheva^1,2, Victoria K Popova¹

¹Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentiev av. 8, 630090 Novosibirsk, Russia.

Molecules (Basel, Switzerland)

|February 24, 2024

概括

亚普塔默可以通过预防病毒聚合和保持血清中的性病毒疗效来增强病毒疗法. 这项研究表明,aptamer NV14t_56可以保护疫苗病毒 (VACV) 免受聚合和免疫成分的影响.

科学领域:

生物技术是生物技术.
分子生物学分子生物学
病毒学病毒学

背景情况:

目前正在研究aptamers是否可以通过预防病毒聚合,增强特异性和提供对抗体的保护来改善病毒疗法.
再组合性瘤病毒,如VV-GMCSF-Lact,是有前途的癌症疗法,但可以受到血清成分和聚合的影响.

研究的目的:

综合研究一种增强病毒疗法的阿巴,重点关注其与疫苗病毒 (VACV) 的相互作用及其保护瘤病毒的潜力.
为了描述阿巴胺NV14t_56,评估其与VV-GMCSF-Lact的结合和聚合抑制,并评估其在人体血清中的免疫屏蔽特性.

主要方法:

选择和优化对抗疫苗病毒 (VACV) 的体.
鉴定了NV14t_56的特征,包括3D建模,在人血清中的稳定性,使用微尺度热泳 (MST) 的结合亲和力 (Kd,EC50) 和通过动态光散射 (DLS) 的聚合抑制.
在人血清中对阿普塔默病毒复合物的体外疗效测试.

主要成果:

阿帕特默NV14t_56显示高亲和力 (Kd ≈ 0.35μM) 和稳定性在人类血清1小时.
动态光散射证实了aptamers环绕病毒颗粒,在不改变血清中的水力动态直径的情况下抑制聚合物形成.
NV14t_56有效结合了VV-GMCSF-Lact (EC50 = 1.487 × 10^9 PFU/mL),并且血清成分没有破坏阿普坦病毒复合体.

结论:

阿普塔默NV14t_56有效地抑制病毒聚合,并保持人类血清中瘤病毒VV-GMCSF-Lact的稳定性和有效性.
NV14t_56显示出作为抗瘤病毒的保护剂的潜力,尽管中和抗体的影响需要考虑治疗应用.

关键词:

一个aptamer的应用程序.动态光散射是一种动态光散射.质瘤质瘤是一种微观尺度的热泳是微观的.科性病毒病毒.

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

相关概念视频

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...